Evidence mapPaperPMID 28286779Full record

ReviewJournal of diabetes research2017

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity.

Mostafa Wanees Ahmed El Husseny, Mediana Mamdouh, Sara Shaban, Abdelrahman Ibrahim Abushouk, Marwa Mostafa Mohamed Zaki, Osama M Ahmed, Mohamed M Abdel-Daim

Open access · goldAbstract readReview
In one paragraph

Review in Journal of diabetes research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mostafa Wanees Ahmed El HussenyFaculty of Medicine, Fayoum University, Fayoum, Egypt; NovaMed Medical Research Association, Cairo, Egypt; Fayoum Medical Student Association, Fayoum, Egypt.
Mediana MamdouhFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Sara ShabanFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Abdelrahman Ibrahim AbushoukNovaMed Medical Research Association, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-1399-6487
Marwa Mostafa Mohamed ZakiFaculty of Clinical Pharmacy, Fayoum University, Fayoum, Egypt.
Osama M AhmedPhysiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
Mohamed M Abdel-DaimPharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, 41522, Egypt.ORCID 0000-0002-4341-2713
Fayoum University · EGAin Shams University · EGBeni-Suef University · EGSuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipokines are bioactive molecules that regulate several physiological functions such as energy balance, insulin sensitization, appetite regulation, inflammatory response, and vascular homeostasis. They include proinflammatory cytokines such as adipocyte fatty acid binding protein (A-FABP) and anti-inflammatory cytokines such as adiponectin, as well as vasodilator and vasoconstrictor molecules. In obesity and type II diabetes mellitus (DM), insulin resistance causes impairment of the endocrine function of the perivascular adipose tissue, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and an increased production of reactive oxygen species. Recent studies have shown that targeting plasma levels of adipokines or the expression of their receptors can increase insulin sensitivity, improve vascular function, and reduce the risk of cardiovascular morbidity and mortality. Several reviews have discussed the potential of adipokines as therapeutic targets for type II DM and obesity; however, this review is the first to focus on their therapeutic potential for vascular dysfunction in type II DM and obesity.

Indexed as

AdipokinesAnimalsDiabetes Mellitus, Type 2Endothelium, VascularHumansObesityAdipokines

Identifiers

PMID28286779
PMCPMC5327767
OpenAlexW2588141807

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.